Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study.
Five premenopausal women with leiomyomata uteri were treated with leuprolide for 3 months and demonstrated a reduction in mean uterine volume of 49%. Cyclic conjugated equine estrogens and MPA were added to leuprolide therapy during the ensuing 24 months, with no significant changes in mean uterine volume or peripheral bone density.
Friedman
A J
AJ
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
D001842:Bone and Bones / Q000473:pathology; D002979:Climacteric / Q000187:drug effects; D004334:Drug Administration Schedule; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy*; D016729:Leuprolide; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D010865:Pilot Projects; D014463:Ultrasonography; D014594:Uterine Neoplasms / Q000188:drug therapy*; D014599:Uterus / Q000473:pathology
D004966:Estrogens, Conjugated (USP); D007987:Gonadotropin-Releasing Hormone; D017258:Medroxyprogesterone Acetate; D016729:Leuprolide; D008525:Medroxyprogesterone